In the endeavour to develop a model for studying gene therapy of cancers associated with human papillomaviruses (HPVs), mouse cells were transformed with the HPV type 16 (HPV16) and activated H-ras oncogenes. This was done by cotransfection of plasmid p16HHMo, carrying the HPV16 E6/E7 oncogenes, and plasmid pEJ6.6, carrying the gene coding for human H-ras oncoprotein activated by the G12V mutation, into secondary C57BL/6 mouse kidney cells. An oncogenic cell line, designated MK16/1/IIIABC, was derived. The epithelial origin of the cells was confirmed by their expression of cytokeratins. No MHC class I and class II molecules were detected on the surface of MK16/1/IIIABC cells. Spontaneous metastases were observed in lymphatic nodes and lungs after prolonged growth of MK16/1/IIIABC-induced subcutaneous tumours. Lethally irradiated MK16/1/IIIABC cells induced protection against challenge with 10(5) homologous cells, but not against a higher cell dose (5 x 10(5)). Plasmids p16HHMo and pEJ6.6 were also used for preventive immunization of mice. In comparison with a control group injected with pBR322, they exhibited moderate protection, in terms of prolonged survival, against MK16/1/IIIABC challenge (P < 0.03). These data suggest that MK16/1/IIIABC cells may serve as a model for studying immune reactions against HPV16-associated human tumours.

Department of Experimental Virology Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Br J Cancer. 1994 Jun;69(6):1176-81 PubMed

J Natl Cancer Inst. 1997 Nov 19;89(22):1664-6 PubMed

Int J Gynecol Cancer. 1993 Mar;3(2):103-109 PubMed

Virology. 1995 Feb 20;207(1):260-70 PubMed

Acta Virol. 1996 Nov-Dec;40(5-6):281-8 PubMed

Virology. 1996 Jun 1;220(1):1-9 PubMed

Br J Cancer. 1995 Aug;72(2):405-11 PubMed

Adv Cancer Res. 1996;68:1-22 PubMed

J Mol Biol. 1981 Jul 25;150(1):1-14 PubMed

Oncol Rep. 1999 Jan-Feb;6(1):211-5 PubMed

Hematol Oncol Clin North Am. 1999 Feb;13(1):259-73 PubMed

Immunol Lett. 1996 Apr;50(1-2):115-7 PubMed

Hybridoma. 1988 Oct;7(5):495-504 PubMed

Cancer Res. 1996 Jan 1;56(1):21-6 PubMed

Arch Virol. 1975;47(3):257-68 PubMed

Arch Med Res. 1999 Jul-Aug;30(4):269-74 PubMed

J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 PubMed

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8 PubMed

J Immunol. 1992 Apr 15;148(8):2617-21 PubMed

Int J Cancer. 1998 Jul 29;77(3):470-5 PubMed

Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):110-4 PubMed

J Natl Cancer Inst. 1997 Feb 19;89(4):280-1 PubMed

Oncogene Res. 1988 Sep;3(2):167-75 PubMed

Neoplasma. 1991;38(4):439-46 PubMed

Int J Cancer. 1993 Jun 19;54(4):594-606 PubMed

Folia Biol (Praha). 1996;42(3):73-8 PubMed

Cell. 1982 May;29(1):161-9 PubMed

J Exp Med. 1998 Dec 21;188(12):2357-68 PubMed

Int J Oncol. 1999 Mar;14(3):593-7 PubMed

Semin Cancer Biol. 1996 Dec;7(6):309-15 PubMed

Infect Immun. 1978 Jun;20(3):587-91 PubMed

Nucleic Acids Res. 1976 Sep;3(9):2303-8 PubMed

J Virol. 1987 Apr;61(4):962-71 PubMed

J Pathol. 1991 Jul;164(3):215-24 PubMed

Biotechniques. 1993 Sep;15(3):532-4, 536-7 PubMed

The Present and Future of Virology in the Czech Republic-A New Phoenix Made of Ashes?

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes

Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours

Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases